Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Future Oncology

• Publication date

  2015-02-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon.15.34PMID 25708426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

  2015cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

  2013cited by this paper
• Abstract P2-15-02: Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients

  2013cited by this paper
• Abstract P2-15-04: Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: The HERA trial experience

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013cited by this paper
• Estrogen receptor in HER2-positive early breast cancer: Two different diseases?

  2012cited by this paper
• Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

  2012cited by this paper
• Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study

  2012cited by this paper
• Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting. J Clin Oncol 30, 2012 (suppl; abstr 586)

  2012cited by this paper
• Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the United Kingdom, Germany, France, Spain, and Italy (EU-5): Results from a physician survey.

  2012cited by this paper
• Outcome of HER2-positive breast cancer patients following metastatic relapse after adjuvant trastuzumab treatment since EMA regulatory approval.

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome.

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.

  2011cited by this paper
• Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

  2010cited by this paper
• HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit.

  2010cited by this paper
• First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting.

  2010cited by this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009cited by this paper
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  2009cited by this paper
• Observational Demetra study: Survival of metastatic breast carcinoma patients after treatment with trastuzumab

  2008cited by this paper
• Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.

  2008cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Adjuvant trastuzumab for HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper

• Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS

  2023cites this paper
• Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS.

  2023cites this paper
• Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

  2020cites this paper
• Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer

  2019cites this paper
• Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort

  2019cites this paper
• Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer

  2018cites this paper
• Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

  2017cites this paper
• REVIEWARTICLE Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer

  2016cites this paper
• Germline determinants of clinical outcome of cutaneous melanoma

  2016cites this paper
• Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer

  2016cites this paper
• HER2-positive metastatic breast cancer: a changing scenario.

  2015cites this paper